Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.

@article{Verma2010SurvivalOF,
  title={Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.},
  author={Dushyant Verma and Hagop M Kantarjian and Jianqin Shan and Susan M O'Brien and Zeev Estrov and Guillermo Garcia-Manero and Charles Koller and Gautam Borthakur and Jorge E. Cortes},
  journal={Cancer},
  year={2010},
  volume={116 11},
  pages={2673-81}
}
BACKGROUND Clonal evolution is frequently detected in patients developing resistance to imatinib. The outcome of patients with clonal evolution treated with second generation tyrosine kinase inhibitors is not known. METHODS The authors analyzed the outcome of 177 CML patients after second tyrosine kinase inhibitor therapy. RESULTS Ninety-five patients were in chronic phase, 30 had clonal evolution, 28 were in accelerated phase (AP), and 24 were in AP plus clonal evolution. Major cytogenetic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Management of CML-blast crisis.

Best practice & research. Clinical haematology • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…